Delivery Order SPE2DR25D1202-SPE2DR26F74DH
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $11,846.39 to AmerisourceBergen Drug Corp for the supply of Glimepiride 4 mg tablets in a quantity of 100 units. This competitive award, issued on December 1, 2025, with an ultimate completion date of December 2, 2025, represents a firm fixed-price transaction with no set-aside designation. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency awarded a delivery order valued at $1,950.84 to AmerisourceBergen Drug Corp for the supply of Glimepiride 4 mg tablets in quantities of 100 units. This is a firm fixed-price, competitively awarded contract with an ultimate completion date of January 16, 2026. The contract has no set-aside designation and will be performed at the awardee's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a subsidiary of Cencora, Inc., is a major pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $3,019.18 to Amerisourcebergen Drug Corp for the supply of Glimepiride 2 mg tablets (100-count packages) on January 7, 2026, with an ultimate completion date of January 8, 2026. This firm fixed-price, non-set-aside contract represents a task order under Amerisourcebergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop Support Medical, valued at up to $999,999,999.00 through December 31, 2031....
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,834.01 to AmerisourceBergen Drug Corp on January 15, 2026, for the supply of Glimepiride 2 mg tablets (100 count). This is a firm fixed-price, non-set-aside contract with an ultimate completion date of January 16, 2026 and performance to be executed at the contractor's Conshohocken, Pennsylvania facility. The award represents a task order under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,157.52 to AmerisourceBergen Drug Corp for the supply of Glimepiride 4 mg tablets (100 count) on July 22, 2025, with an ultimate completion date of July 23, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the vendor's Conshohocken, Pennsylvania location. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving federal medical...
- The Defense Logistics Agency awarded a delivery order valued at $5,577.55 to AmerisourceBergen Drug Corp for the supply of Glimepiride 4 mg tablets in quantities of 100, with an ultimate completion date of October 23, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed price terms and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's established role as a critical...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $2,130.48 by the Defense Logistics Agency (DLA) on December 5, 2025, for the supply of Glimepiride 4 mg tablets (100-count units). This is a firm fixed price delivery order with an ultimate completion date of December 8, 2025, and represents a non-competitive, non-set-aside procurement. The award falls under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $2,968.93 to AmerisourceBergen Drug Corp for the supply of Glimepiride 4 mg tablets (100-count units) under a firm fixed price contract. The award, issued on September 12, 2025, with an ultimate completion date of September 15, 2025, represents a non-set-aside competitive procurement. Performance will be executed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Glimepiride 4 mg tablets (100-count units) with a ceiling value of $1,229.86. The award, issued on December 18, 2025, with an ultimate completion date of December 19, 2025, represents a firm fixed-price delivery order with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical federal...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Glimepiride 4 mg tablets in quantities of 100 units under a firm fixed-price contract valued at $1,411.27. The order, issued on January 5, 2026, with an ultimate completion date of January 6, 2026, represents a non-competitive delivery order executed under an existing contract vehicle. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken,...
- SPE2DR25D1202Indefinite Delivery Contract
- SPE2DR25D1202-SPE2DR26F74DHDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,280.16 to Amerisourcebergen Drug Corp for the supply of Glimepiride 4 mg tablets (100-count units). This firm fixed-price contract, issued on January 20, 2026, with completion scheduled for January 21, 2026, represents a non-set-aside competitive award. Amerisourcebergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor that serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. The company operates as a subsidiary of Cencora, Inc., which does business as Amerisourcebergen. This delivery order was executed under Amerisourcebergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical supply vehicle valued at $999.99 billion through December 2026. The IDC enables the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs globally, including specialty medications, brand-name and generic drugs, vaccines, and related medical commodities across multiple therapeutic domains. Glimepiride, a diabetes management medication, aligns with Amerisourcebergen's extensive portfolio of chronic disease treatments delivered through this strategic federal contract vehicle.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.3k | 1/19/26 |